Post-injury neuroprotective effects of the thalidomide analog 3,6′-dithiothalidomide on traumatic brain injury

Buyandelger Batsaikhan, Jing Ya Wang, Michael T. Scerba, David Tweedie, Nigel H. Greig, Jonathan P. Miller, Barry J. Hoffer, Chih Tung Lin, Jia Yi Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Long-term deficits after TBI arise not only from the direct effects of the injury but also from ongoing processes such as neuronal excitotoxicity, inflammation, oxidative stress and apoptosis. Tumor necrosis factor-α (TNF-α) is known to contribute to these processes. We have previously shown that 3,6′-dithiothalidomide (3,6′-DT), a thalidomide analog that is more potent than thalidomide with similar brain penetration, selectively inhibits the synthesis of TNF-α in cultured cells and reverses behavioral impairments induced by mild TBI in mice. In the present study, we further explored the therapeutic potential of 3,6′-DT in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact. A single dose of 3,6′-DT (28 mg/kg, i.p.) at 5 h after TBI significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits at 24 h post-injury. Expression of pro-inflammatory cytokines in the contusion regions were also suppressed at the transcription and translation level by 3,6′-DT. Notably, neuronal oxidative stress was also suppressed by 3,6′-DT. We conclude that 3,6′-DT may represent a potential therapy to ameliorate TBI-induced functional deficits.

Original languageEnglish
Article number502
JournalInternational Journal of Molecular Sciences
Volume20
Issue number3
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

brain damage
Thalidomide
Neuroprotective Agents
Brain
analogs
Wounds and Injuries
Contusions
necrosis
apoptosis
Oxidative stress
Oxidative Stress
Tumor Necrosis Factor-alpha
Cell death
Brain Concussion
Apoptosis
tumors
disabilities
animal models
degeneration
mortality

Keywords

  • 3,6′-dithiothalidomide
  • Neurodegeneration
  • Neuroinflammation
  • Neurological deficits
  • Oxidative stress
  • Traumatic brain injury

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Post-injury neuroprotective effects of the thalidomide analog 3,6′-dithiothalidomide on traumatic brain injury. / Batsaikhan, Buyandelger; Wang, Jing Ya; Scerba, Michael T.; Tweedie, David; Greig, Nigel H.; Miller, Jonathan P.; Hoffer, Barry J.; Lin, Chih Tung; Wang, Jia Yi.

In: International Journal of Molecular Sciences, Vol. 20, No. 3, 502, 01.02.2019.

Research output: Contribution to journalArticle

Batsaikhan, Buyandelger ; Wang, Jing Ya ; Scerba, Michael T. ; Tweedie, David ; Greig, Nigel H. ; Miller, Jonathan P. ; Hoffer, Barry J. ; Lin, Chih Tung ; Wang, Jia Yi. / Post-injury neuroprotective effects of the thalidomide analog 3,6′-dithiothalidomide on traumatic brain injury. In: International Journal of Molecular Sciences. 2019 ; Vol. 20, No. 3.
@article{b0192cfd7f94432589d0701124ac7519,
title = "Post-injury neuroprotective effects of the thalidomide analog 3,6′-dithiothalidomide on traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Long-term deficits after TBI arise not only from the direct effects of the injury but also from ongoing processes such as neuronal excitotoxicity, inflammation, oxidative stress and apoptosis. Tumor necrosis factor-α (TNF-α) is known to contribute to these processes. We have previously shown that 3,6′-dithiothalidomide (3,6′-DT), a thalidomide analog that is more potent than thalidomide with similar brain penetration, selectively inhibits the synthesis of TNF-α in cultured cells and reverses behavioral impairments induced by mild TBI in mice. In the present study, we further explored the therapeutic potential of 3,6′-DT in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact. A single dose of 3,6′-DT (28 mg/kg, i.p.) at 5 h after TBI significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits at 24 h post-injury. Expression of pro-inflammatory cytokines in the contusion regions were also suppressed at the transcription and translation level by 3,6′-DT. Notably, neuronal oxidative stress was also suppressed by 3,6′-DT. We conclude that 3,6′-DT may represent a potential therapy to ameliorate TBI-induced functional deficits.",
keywords = "3,6′-dithiothalidomide, Neurodegeneration, Neuroinflammation, Neurological deficits, Oxidative stress, Traumatic brain injury",
author = "Buyandelger Batsaikhan and Wang, {Jing Ya} and Scerba, {Michael T.} and David Tweedie and Greig, {Nigel H.} and Miller, {Jonathan P.} and Hoffer, {Barry J.} and Lin, {Chih Tung} and Wang, {Jia Yi}",
year = "2019",
month = "2",
day = "1",
doi = "10.3390/ijms20030502",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - Post-injury neuroprotective effects of the thalidomide analog 3,6′-dithiothalidomide on traumatic brain injury

AU - Batsaikhan, Buyandelger

AU - Wang, Jing Ya

AU - Scerba, Michael T.

AU - Tweedie, David

AU - Greig, Nigel H.

AU - Miller, Jonathan P.

AU - Hoffer, Barry J.

AU - Lin, Chih Tung

AU - Wang, Jia Yi

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Long-term deficits after TBI arise not only from the direct effects of the injury but also from ongoing processes such as neuronal excitotoxicity, inflammation, oxidative stress and apoptosis. Tumor necrosis factor-α (TNF-α) is known to contribute to these processes. We have previously shown that 3,6′-dithiothalidomide (3,6′-DT), a thalidomide analog that is more potent than thalidomide with similar brain penetration, selectively inhibits the synthesis of TNF-α in cultured cells and reverses behavioral impairments induced by mild TBI in mice. In the present study, we further explored the therapeutic potential of 3,6′-DT in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact. A single dose of 3,6′-DT (28 mg/kg, i.p.) at 5 h after TBI significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits at 24 h post-injury. Expression of pro-inflammatory cytokines in the contusion regions were also suppressed at the transcription and translation level by 3,6′-DT. Notably, neuronal oxidative stress was also suppressed by 3,6′-DT. We conclude that 3,6′-DT may represent a potential therapy to ameliorate TBI-induced functional deficits.

AB - Traumatic brain injury (TBI) is a major cause of mortality and disability worldwide. Long-term deficits after TBI arise not only from the direct effects of the injury but also from ongoing processes such as neuronal excitotoxicity, inflammation, oxidative stress and apoptosis. Tumor necrosis factor-α (TNF-α) is known to contribute to these processes. We have previously shown that 3,6′-dithiothalidomide (3,6′-DT), a thalidomide analog that is more potent than thalidomide with similar brain penetration, selectively inhibits the synthesis of TNF-α in cultured cells and reverses behavioral impairments induced by mild TBI in mice. In the present study, we further explored the therapeutic potential of 3,6′-DT in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact. A single dose of 3,6′-DT (28 mg/kg, i.p.) at 5 h after TBI significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits at 24 h post-injury. Expression of pro-inflammatory cytokines in the contusion regions were also suppressed at the transcription and translation level by 3,6′-DT. Notably, neuronal oxidative stress was also suppressed by 3,6′-DT. We conclude that 3,6′-DT may represent a potential therapy to ameliorate TBI-induced functional deficits.

KW - 3,6′-dithiothalidomide

KW - Neurodegeneration

KW - Neuroinflammation

KW - Neurological deficits

KW - Oxidative stress

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85060518362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060518362&partnerID=8YFLogxK

U2 - 10.3390/ijms20030502

DO - 10.3390/ijms20030502

M3 - Article

C2 - 30682785

AN - SCOPUS:85060518362

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 3

M1 - 502

ER -